Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

Creative Commons License

Mishra R. R., Belder N., Ansari S. A., Kayhan M., Bal H., Raza U., ...More

CLINICAL CANCER RESEARCH, vol.24, no.8, pp.1987-2001, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 8
  • Publication Date: 2018
  • Doi Number: 10.1158/1078-0432.ccr-17-2776
  • Journal Name: CLINICAL CANCER RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1987-2001
  • Hacettepe University Affiliated: Yes

Abstract

Purpose: Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms of tamoxifen resistance and provide actionable drug targets overcoming resistance.